AR-9281

Research use only, not for human use.

AR9281 is a potent and selective inhibitor of soluble epoxide hydrolase (s-EH) potentially for the treatment of hypertension and type 2 diabetes.

AR9281 is a potent and selective inhibitor of soluble epoxide hydrolase (s-EH) potentially for the treatment of hypertension and type 2 diabetes.

AR-9281 (APAU) has inhibitory activity for human sEH (HsEH) and murine sEH (MsEH) with IC50 values of 13.8 nM and 1.7 nM, respectively.

AR-9281 (APAU) (oral, 150-200 mg/dL, for 6 weeks) enhances the therapeutic effects of EETs, slows progression of hyperglycemia, protects the myocyte structure, and reduces Ca2+ dysregulation and SERCA remodeling in hyperglycemic rats. Animal Model:T2DM rat model Dosage:150-200 mg/dL Administration:oral(drinking), for 6 weeks Result:Attenuated the progressive increase of blood glucose concentration and preserved mitochondrial structure and myofibril morphology in cardiac myocytes.Protected the intracellular Ca2+ effector system. Had less downregulation of sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA) and lowed expression of hypertrophic markers.

APAU

Others

Other Targets

s-EH

——

——

913548-29-5

319.44

C18H29N3O2

>98% (HPLC)

DMSO:25 mg/mL (78.26 mM; Need ultrasonic)

CC(=O)N1CCC(CC1)NC(=O)NC23CC4CC(CC(C4)C2)C3

——

(-20℃)

With Ice Pack

≥ 2 years